AMPLITUDE-O Trial
1/5
Cardiovascular outcome trial for Efpeglenatide an investigational once weekly Exendin-4 based GLP-1ra.
What are the unanswered questions
Do Exendin-based GLP-1a ⤵️ MACE❓
Do GLP-1ra ⤵️ MACE in people taking SGLT2i❓
Does GLP-1ra ⤵️ renal decline❓
#ADA2021
2/5
Main results
Efpeglenatide
⤵️3-point MACE by 27%
⤵️expanded MACE by 21%
⤵️Renal composite by 32%
⤵️MACE or non-CV death by 27%
Best data yet to suggest adding GLP-1ra to SGLT2i ⤵️MACE
@DLBHATTMD
3/5
Renal outcomes
Efpeglenatide
⤵️Renal composite
⤵️Albuminuria
⤵️eGFR slope❗️
4/5
How do these results impact on an updated GLP-1ra CVOT meta-analysis?
GLP-1ra
⤵️3-point MACE by 14%
⤵️CV ☠️ by 13%
⤵️MI by 10%
⤵️Stoke by 17%
⤵️hHF by 11%
5/5
Conclusions
Do Exendin-based GLP-1a ⤵️ MACE?✅
Do GLP-1ra ⤵️ MACE in people taking SGLT2i?✅ (⚠️small numbers though)
Does GLP-1ra ⤵️ renal decline?✅
Full slide set
👇
phri.ca/research/ampli…
Full paper
👇
nejm.org/doi/full/10.10…
Oops. Wong images attached 🤦♂️
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.